Method of detecting lung disease

a lung disease and lung technology, applied in the field of lung disease diagnostic assays, can solve the problems of lung infection serious problem and toxic side effects, and achieve the effects of hydrate lung mucus secretions

Inactive Publication Date: 2000-10-17
THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
View PDF10 Cites 51 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

Also disclosed is a method of facilitating the obtaining of a mucus sample from at least one lung of a subject, comprising administering to at least one lung of said subject, in an amount effective to hydrate lung mucous secretions, and/or stimulate mucus secretions therein, and/or stimulate ciliary beat frequency therein, a compound of Formula (I) as given above, or a pharmaceutically acceptable salt thereof, and then collecting a mucus sample from said at least one lung of said subject. The mucus samples collected may then be analyzed for the presence or absence of lung diseas...

Problems solved by technology

In particular, microbial infections of the lung are a serious problem in patients afflicted with acquired immune deficiency ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Delivery of UTP followed by Hypertonic Saline

A subject is caused to inhale an aerosol of UTP solution (10.sup.-2 M UTP in 0.9% (by weight) sterile pyrogen-free saline solution) delivered by a

Pari LC Plus nebulizer for 10 minutes. Immediately afterwards, the subject is caused to inhale an aerosol of hypertonic saline solution (3% sterile pyrogen-free saline solution), delivered by a nebulizer for 10 minutes. During inhalation of the aerosols and after inhalation of the aerosols, the subject is encouraged to cough, and all sputum is collected during aerosol inhalation and over a 20 minute interval following cessation of aerosol inhalation. The sputum is captured in a plastic sputum container. The sputum so obtained is analyzed for content pending the clinical requirement, including analyses of cytologies for pulmonary neoplasm, and the presence of infectious agents, for example, Pneumocystis carinii, by silver staining and immunofluorescence techniques. The technique is applicable for...

example 2

Delivery of UTP with Amiloride

This example is carried out in essentially the same manner as example 1 above, except that the UTP is dissolved in a 0.12% sterile pyrogen-free NaCl solution, and the solution also contains 10.sup.-2 M amiloride.

example 3

Delivery of Hypertonic Saline followed by UTP

This Example is carried out in essentially the same manner as Example 1 above, except that the hypertonic saline solution is delivered first, and the UTP solution is delivered immediately thereafter. Durations of delivery and concentrations remain the same.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Frequencyaaaaaaaaaa
Login to view more

Abstract

A method of facilitating the obtaining of a mucus sample from at least one lung of a subject comprises administering to at least one lung of the subject, in an amount effective to hydrate lung mucous secretions and/or stimulate cilia beat frequency therein, uridine 5'-triphosphate, an active analog thereof, or a pharmaceutically acceptable salt of either thereof, and, optionally, concurrently administering to said at least one lung a physiologically acceptable salt in an amount effective to hydrate lung mucus secretions therein. A sputum or mucus sample is then collected from said at least one lung, which sample can then be analyzed for lung disease. Pharmaceutical compositions useful for carrying out the method comprise UTP or a salt thereof, alone or in combination with a physiologically acceptable salt, or a pharmaceutically acceptable salt of either thereof. The composition may be a liquid/liquid suspension composition or a dry powder composition.

Description

FIELD OF THE INVENTIONThis application concerns lung diagnostic assays in general, and particularly concerns a lung diagnostic assay in which lung mucus secretions are hydrated to facilitate collection thereof.BACKGROUND OF THE INVENTIONThe analysis of sputum samples is particularly important in the treatment and diagnosis of many lung disorders, including lung cancer and tuberculosis (TB).In particular, microbial infections of the lung are a serious problem in patients afflicted with acquired immune deficiency syndrome (AIDS). Two particularly problematic infections are Pneumocystis carinii pneumonia infections and mycobacterial infections.Pneumocystis carinii pneumonia infections are typically referred to as "PCP" infections. It is now estimated that approximately 70 percent of patients afflicted with AIDS will contract this disease. PCP may be treated with pentamidine isethionate, but an unfortunate side effect of this treatment is its toxicity. Accordingly, there is a continued ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K33/14A61K45/00A61K45/06A61B5/00A61B10/00A61K9/00A61K31/495C07H19/10A61K31/675A61K31/7064A61P11/10C07G99/00C07H19/04C07H19/06C08J11/08C12Q1/00C12Q1/48G01N33/48
CPCA61K9/0078A61K33/14A61K45/06A61K31/70A61K31/495A61K31/66A61K31/7004A61K31/165A61K31/14A61K2300/00A61P11/10
Inventor BOUCHER, JR., RICHARD C.
Owner THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products